In the context of graft-versus-leukemia (GVL), organoid models have provided insights into the role of RIP1 inhibition in improving immune reconstitution and reducing graft-versus-host disease (GVHD) mortality while preserving GVL effects [50]. Here, RIPK1 is linked to graft versus host disease.